5th STING And TLR-Targeted Therapies Summit 2024

Kongressthemen
The innate immune system is increasingly being recognised as a target for a range of exciting applications with high unmet need, from those difficult to treat cancers to infectious and inflammatory disease.

The past year has seen a mix of ups and downs for this space, with several companies entering the clinic, emerging new modalities of STING/TLR agonists and on the other side some clinical setbacks.

Wissenschaftliche Fach-Gesellschaft
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/2277808-3?pid=4832

Speakers: Aarron Willingham, Executive Director, Merck and Co, Anna Galkin, CSO, Axelia Oncology and more.

https://go.evvnt.com/2277808-2?pid=4832

Frau Abigail Cox